Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside?
Despite considerable effort focusing on designing and finding efficient anti-cancer drugs over the last decade, little progress has been achieved, in particular in case of highly recalcitrant malignancies. Also, since there is a trend suggesting that deaths from cancers may be more frequent than from cardiovascular diseases, it is important to look for novel efficient and selective therapeutic approaches to gradually start winning the battle with cancer. Redox-silent vitamin E analogues, epitomised by alpha-tocopheryl succinate, give some hope in the quest for drugs with such properties. Thus far, these agents have been successfully tested in experimental animals with different types of cancer, showing high efficacy against malignancies including HER2-positive breast carcinomas or malignant mesotheliomas. Further research will provide additional, necessary data to launch clinical trials, possibly in near future, translating into development of innovative anti-cancer drugs acting by targeting mitochondria selectively in cancer cells.
Zhao
Yan
Y
Department of Nutrition and Food, Harbin Medical University, Harbin, Heilongjiang Province, China.
Neuzil
Jiri
J
Wu
Kun
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D015195:Drug Design; D005260:Female; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy*; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D024502:alpha-Tocopherol / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014810:Vitamin E; D024502:alpha-Tocopherol